While no universal VAF threshold exists for identifying key driver mutations, a study evaluating the effect of TP53 mutation VAF on survival in hematological malignancies found that a VAF greater than 6% was associated with profoundly shorter survival and poorer prognosis compared to patients with a TP53 VAF below 6%.17 Here, TP53 is linked to hematologic disorder.